Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Am J Infect Control ; 44(3): 315-9, 2016 Mar 01.
Article in English | MEDLINE | ID: mdl-26619947

ABSTRACT

BACKGROUND: Management of pressure ulcers (PrUs) in patients with gunshot-spinal cord injuries (SCIs) presents unique medical and economic challenges for practitioners. METHODS: A retrospective chart review was conducted at 3 acute care hospitals in metropolitan Detroit for patients admitted with PrUs due to gunshot-SCIs between January 2004 and December 2008. Multivariate analysis using logistic regression was conducted to choose for the independent predictors of infected PrUs. Mean adjusted in-hospital costs per patient and per hospitalization were calculated and compared between infected and noninfected PrUs. RESULTS: The study cohort included 201 gunshot-SCI patients with PrUs contributing to 395 admissions, including readmissions, between 2004 and 2008. Seventy-six patients (38%) had infected PrUs at time of the index admission. Independent predictors of infected PrUs on index admission included Charlson Comorbidity Index ≥2 (odds ratio, 2.18, P = .026) and stage III/IV PrU (odds ratio, 4.82; P <.0001). During the study period, the cumulative median duration of hospitalization per patient was 12 days (interquartile range, 6-24 days), resulting in a mean adjusted cost of $19,969 ± $6639 per patient. The mean adjusted cost per hospitalization for patients with infected PrUs was significantly higher than that for patients with noninfected PrUs ($16,735 ± $8310 vs $12,356 ± $7007; P <.001). CONCLUSIONS: A multidisciplinary approach including home-based rehabilitation programs and SCI wound clinics might help prevent PrUs and their complications and reduce associated costs.


Subject(s)
Hospital Costs , Pressure Ulcer/epidemiology , Pressure Ulcer/therapy , Spinal Cord Injuries/complications , Adult , Female , Humans , Male , Michigan/epidemiology , Middle Aged , Pressure Ulcer/economics , Retrospective Studies , Risk Factors
2.
Am J Infect Control ; 43(7): 719-23, 2015 Jul 01.
Article in English | MEDLINE | ID: mdl-25934068

ABSTRACT

BACKGROUND: Extended-spectrum ß-lactamase (ESBL)-producing pathogens represent increasing challenges to physicians because of rising prevalence, high mortality, and challenging treatment. Identifying high risks and early appropriate therapy is critical to favorable outcomes. METHODS: This is a 5-year retrospective case-case-control study performed at the Detroit Medical Center on adult patients with bloodstream infection (BSI) caused by ESBL-producing and non-ESBL-producing Escherichia coli or Klebsiella pneumoniae, each compared with uninfected controls. Data were collected from December 2004-August 2009. Multivariate analysis was performed using logistic regression. RESULTS: Participants included 103 patients with BSI caused by ESBL-producing pathogens and 79 patients with BSI caused by pathogens that did not produce ESBLs. The mean age of patients in the ESBL group was 67 years; of the patients, 51% were men, 77% were black, and 38% (n = 39) died in hospital. The mean age of patients in the non-ESBL group was 58 years; of the patients, 51% were men, 92% were black, and 22% (n = 17) died in hospital. On multivariate analysis, predictors of BSI caused by ESBL-producing pathogens included central venous catheter (odds ratio [OR], 29.4; 95% confidence interval [CI], 3.0-288.3), prior ß-lactam-/ß-lactamase-inhibitor therapy (OR, 28.1; 95% CI, 1.99-396.5), and prior cefepime therapy (OR, 22.7; 95% CI, 2.7-192.4). The only risk factor for BSI caused by non-ESBL-producing pathogens was urinary catheter insertion (OR, 18.2; 95% CI, 3.3-100.3). CONCLUSION: Prior antimicrobial therapy, particularly with ß-lactam, was the strongest unique risk factor for BSI caused by ESBL-producing E coli or K pneumoniae.


Subject(s)
Bacteremia/epidemiology , Cephalosporins/therapeutic use , Escherichia coli Infections/epidemiology , Escherichia coli/enzymology , Klebsiella Infections/epidemiology , Klebsiella pneumoniae/enzymology , beta-Lactamases/metabolism , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/therapeutic use , Bacteremia/microbiology , Case-Control Studies , Cefepime , Escherichia coli/isolation & purification , Escherichia coli Infections/microbiology , Female , Hospitals , Humans , Klebsiella Infections/microbiology , Klebsiella pneumoniae/isolation & purification , Male , Michigan/epidemiology , Middle Aged , Retrospective Studies , Risk Factors
3.
Infect Control Hosp Epidemiol ; 33(12): 1250-4, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23143365

ABSTRACT

A retrospective case-case control study was conducted, including 60 cases with daptomycin-nonsusceptible vancomycin-resistant enterococci (DNS-VRE) matched to cases with daptomycin-susceptible VRE and to uninfected controls (1∶1∶3 ratio). Immunosuppression, presence of comorbid conditions, and prior exposure to antimicrobials were independent predictors of DNS-VRE, although prior daptomycin exposure occurred rarely. In summary, a case-case control study identified independent risk factors for the isolation of DNS-VRE: immunosuppression, multiple comorbid conditions, and prior exposures to cephalosporines and metronidazole.


Subject(s)
Anti-Bacterial Agents/pharmacology , Daptomycin/pharmacology , Drug Resistance, Multiple, Bacterial , Enterococcus faecalis/drug effects , Enterococcus faecium/drug effects , Gram-Positive Bacterial Infections/epidemiology , Vancomycin/pharmacology , Adult , Aged , Case-Control Studies , Cephalosporins/therapeutic use , Comorbidity , Female , Gram-Positive Bacterial Infections/microbiology , Humans , Immunosuppression Therapy , Male , Metronidazole/therapeutic use , Middle Aged , Proportional Hazards Models , Retrospective Studies , Risk Factors , Statistics, Nonparametric , Vancomycin Resistance
4.
Antimicrob Agents Chemother ; 56(5): 2452-8, 2012 May.
Article in English | MEDLINE | ID: mdl-22354290

ABSTRACT

In published studies, cohorts of patients with bacteremia due to vancomycin-resistant Enterococcus (VRE) have predominantly been infected with Enterococcus faecium. Little is known about the epidemiology and outcomes associated with bacteremia due to VR Enterococcus faecalis. A retrospective study of isolates obtained from January 2008 to October 2010 was conducted at Detroit Medical Center (DMC). Unique patients with blood cultures positive for VRE were reviewed. Outcomes were analyzed using logistic regression. During the study period, 105 cases of bacteremia due to VR E. faecalis and 197 cases of bacteremia due to VR E. faecium were identified. The mean age in the study cohort was 61.5 ± 15 years; 162 subjects (53.6%) were male. After controlling for a propensity score, bacteremia due to VR E. faecalis was associated with >2-fold-lower in-hospital mortality than bacteremia due to VR E. faecium. Interestingly, bacteremia due to VR E. faecalis was associated with longer hospital stay after VRE isolation, although total length of stay was similar for groups with VR E. faecalis and VR E. faecium. Bacteremia due to VR E. faecalis was associated with a >2-fold-lower risk for mortality than bacteremia due to VR E. faecium, possibly due to the availability of ß-lactam therapeutics for treatment of VR E. faecalis.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Bacteremia/drug therapy , Enterococcus faecalis/pathogenicity , Enterococcus faecium/pathogenicity , Gram-Positive Bacterial Infections/drug therapy , Vancomycin/administration & dosage , beta-Lactams/administration & dosage , Adult , Aged , Anti-Bacterial Agents/therapeutic use , Bacteremia/epidemiology , Bacteremia/microbiology , Bacteremia/mortality , Enterococcus faecalis/isolation & purification , Enterococcus faecium/isolation & purification , Female , Gram-Positive Bacterial Infections/epidemiology , Gram-Positive Bacterial Infections/microbiology , Gram-Positive Bacterial Infections/mortality , Hospital Mortality , Humans , Logistic Models , Male , Middle Aged , Retrospective Studies , Risk Factors , Treatment Outcome , United States/epidemiology , Vancomycin/therapeutic use , Vancomycin Resistance , beta-Lactams/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...